Feature

Nature Biotechnology 25, 1395 - 1402 (2007)
Corrected online: 8 April 2008 | doi:10.1038/nbt1207-1395

Antivirals become a broader enterprise

Jeffrey L Fox1

Small molecules have dominated antivirals for decades, but other approaches are needed and biologics could show the way.

Top
  1. Jeffrey L. Fox is a contributing writer for Nature Biotechnology.
* In the version of this article initially published, the name of a person quoted on p. 1399 was incorrect. The CSO of Replicor of Laval, QC, Canada, given as "Andrew Toussaint" should be "Andrew Vaillant." The error has been corrected in the HTML and PDF versions of the article.

Extra navigation

Subscribe to Nature Biotechnology

Subscribe

Search PubMed for

natureproducts


ADVERTISEMENT